{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:31:46Z","timestamp":1793734306473,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson\u2019s Disease (PD). However, there remains a scarcity of head-to-head studies that directly compare safinamide and rasagiline. This study compared safinamide and rasagiline as adjuncts to levodopa in Chinese PD patients with motor fluctuations by matching-adjusted indirect comparison. Baseline age, sex, BMI, and OFF time were adjusted for matching. Efficacy outcomes were the mean changes in total daily OFF time, UPDRS III, and PDQ-39 from baseline to week 16, which calculated by a weighted covariance model. Safety outcomes included rates of AEs, SAEs, and DCAEs. Bucher method was used for mean difference (MD) of efficacy and odds ratio (OR) of safety outcomes. Combination therapy of safinamide 50-100\u00a0mg\/day and levodopa significantly reduced the mean total daily OFF time by 0.7\u00a0h (\u2212\u00a01.40 to \u2212\u00a00.02) compared to the combination therapy of rasagiline 1\u00a0mg\/day and levodopa. Safinamide more effectively reduced UPDRS III (\u2212\u00a02.9, \u2212\u00a05.28 to \u2212\u00a00.52). Changes in PDQ-39 scores indicated a trend toward greater improvement in safinamide. There was no significant difference in safety outcomes. Compared to rasagiline, the combined therapy of safinamide and levodopa could significantly improve motor fluctuations for PD patients in China, without compromising safety.<\/jats:p>","DOI":"10.1038\/s41598-025-94960-9","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T20:32:02Z","timestamp":1743021122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson\u2019s disease patients with a matching adjusted indirect comparison"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuyan","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"94960_CR1","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1007\/s12035-022-02799-2","volume":"59","author":"WZC See","year":"2022","unstructured":"See, W. Z. C., Naidu, R. & Tang, K. S. Cellular and molecular events leading to paraquat-induced apoptosis: Mechanistic insights into Parkinson\u2019s disease pathophysiology. Mol. Neurobiol. 59, 3353\u20133369. https:\/\/doi.org\/10.1007\/s12035-022-02799-2 (2022).","journal-title":"Mol. Neurobiol."},{"key":"94960_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta, V. et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur. J. Neurol. 30, 1465\u20131480. https:\/\/doi.org\/10.1111\/ene.15734 (2023).","journal-title":"Eur. J. Neurol."},{"key":"94960_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/jpd-191633","volume":"9","author":"HV Gupta","year":"2019","unstructured":"Gupta, H. V., Lyons, K. E., Wachter, N. & Pahwa, R. Long term response to levodopa in Parkinson\u2019s disease. J. Parkinsons Dis. 9, 525\u2013529. https:\/\/doi.org\/10.3233\/jpd-191633 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"94960_CR4","doi-asserted-by":"publisher","unstructured":"Barrachina-Fern\u00e1ndez, M., Mait\u00edn, A. M., S\u00e1nchez-\u00c1vila, C. & Romero, J. P. Wearable technology to detect motor fluctuations in Parkinson\u2019s disease patients: Current state and challenges. Sens. (Basel) 21. https:\/\/doi.org\/10.3390\/s21124188 (2021).","DOI":"10.3390\/s21124188"},{"key":"94960_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/ene.15651","volume":"30","author":"R Yan","year":"2023","unstructured":"Yan, R. et al. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson\u2019s disease: A network meta-analysis of randomized controlled trials. Eur. J. Neurol. 30, 1118\u20131134. https:\/\/doi.org\/10.1111\/ene.15651 (2023).","journal-title":"Eur. J. Neurol."},{"key":"94960_CR6","unstructured":"Association. (2020) Chinese Parkinson\u2019s disease treatment guidelines (Fourth Edition). Chin. J. Neurol. 53, 973-986 (2020)."},{"key":"94960_CR7","first-page":"347","volume":"28","author":"L Wang","year":"2021","unstructured":"Wang, L., Chen, H. & Zhang, Y. The Evidence-Based medicine guidelines for the treatment of motor symptoms in Mid-to-Late stage Parkinson\u2019s disease in China. Chin. J. Neuroimmunol. Neurol. 28, 347\u2013360 (2021).","journal-title":"Chin. J. Neuroimmunol. Neurol."},{"key":"94960_CR8","unstructured":"Parkinson\u2019s disease in adults: Diagnosis and management (National Institute for Health and Care Excellence (NICE) Copyright \u00a9 NICE 2017. (2017)."},{"key":"94960_CR9","doi-asserted-by":"publisher","first-page":"19272","DOI":"10.1038\/s41598-023-44142-2","volume":"13","author":"H Asano","year":"2023","unstructured":"Asano, H. et al. Safety comparisons among monoamine oxidase inhibitors against Parkinson\u2019s disease using FDA adverse event reporting system. Sci. Rep. 13, 19272. https:\/\/doi.org\/10.1038\/s41598-023-44142-2 (2023).","journal-title":"Sci. Rep."},{"key":"94960_CR10","doi-asserted-by":"publisher","unstructured":"Sanchez Alonso, P., De La Casa-Fages, B., Alonso-C\u00e1novas, A. & Mart\u00ednez-Castrillo, J. C. Switching from rasagiline to safinamide as an add-on therapy regimen in patients with levodopa: A literature review. Brain Sci. 13 https:\/\/doi.org\/10.3390\/brainsci13020276 (2023).","DOI":"10.3390\/brainsci13020276"},{"key":"94960_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/01616412.2021.1942408","volume":"43","author":"E Bianchini","year":"2021","unstructured":"Bianchini, E. et al. Switch from rasagiline to safinamide in fluctuating Parkinson\u2019s disease patients: A retrospective, pilot study. Neurol. Res. 43, 950\u2013954. https:\/\/doi.org\/10.1080\/01616412.2021.1942408 (2021).","journal-title":"Neurol. Res."},{"key":"94960_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000527372","volume":"57","author":"Z Zheng","year":"2023","unstructured":"Zheng, Z., Zhu, Z., Zhou, C., Cao, L. & Zhao, G. Burden of Parkinson disease in China, 1990\u20132019: Findings from the 2019 global burden of disease study. Neuroepidemiology 57, 51\u201364. https:\/\/doi.org\/10.1159\/000527372 (2023).","journal-title":"Neuroepidemiology"},{"key":"94960_CR13","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","volume":"36","author":"Q Wei","year":"2022","unstructured":"Wei, Q. et al. The XINDI study: A randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson\u2019s disease with motor fluctuations. CNS Drugs. 36, 1217\u20131227. https:\/\/doi.org\/10.1007\/s40263-022-00958-6 (2022).","journal-title":"CNS Drugs"},{"key":"94960_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40035-018-0119-7","volume":"7","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z. et al. Adjunct rasagiline to treat Parkinson\u2019s disease with motor fluctuations: A randomized, double-blind study in China. Transl. Neurodegener. 7, 14. https:\/\/doi.org\/10.1186\/s40035-018-0119-7 (2018).","journal-title":"Transl. Neurodegener."},{"key":"94960_CR15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1017\/s1461145713000175","volume":"16","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson\u2019s disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int. J. Neuropsychopharmacol. 16, 1529\u20131537. https:\/\/doi.org\/10.1017\/s1461145713000175 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"94960_CR16","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/s12325-023-02546-6","volume":"40","author":"M Dubinsky","year":"2023","unstructured":"Dubinsky, M. et al. Matching-adjusted indirect comparison between risankizumab and ustekinumab for induction and maintenance treatment of moderately to severely active Crohn\u2019s disease. Adv. Ther. 40, 3896\u20133911. https:\/\/doi.org\/10.1007\/s12325-023-02546-6 (2023).","journal-title":"Adv. Ther."},{"key":"94960_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.18553\/jmcp.2022.22005","volume":"28","author":"DM Visco","year":"2022","unstructured":"Visco, D. M. et al. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease. J. Manag Care Spec. Pharm. 28, 892\u2013902. https:\/\/doi.org\/10.18553\/jmcp.2022.22005 (2022).","journal-title":"J. Manag Care Spec. Pharm."},{"key":"94960_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000527403","volume":"12","author":"P Merle","year":"2023","unstructured":"Merle, P. et al. Regorafenib versus cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: An anchored matching-adjusted indirect comparison of efficacy and safety. Liver Cancer  12, 145\u2013155. https:\/\/doi.org\/10.1159\/000527403 (2023).","journal-title":"Liver Cancer"},{"key":"94960_CR19","unstructured":"Phillippo, D. M. et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. Available from http:\/\/www.nicedsu.org.uk (2016)."},{"key":"94960_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher, H. C., Guyatt, G. H., Griffith, L. E. & Walter, S. D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50, 683\u2013691. https:\/\/doi.org\/10.1016\/s0895-4356(97)00049-8 (1997).","journal-title":"J. Clin. Epidemiol."},{"key":"94960_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41531-023-00589-8","volume":"9","author":"W Sako","year":"2023","unstructured":"Sako, W. et al. Comparative efficacy and safety of adjunctive drugs to Levodopa for fluctuating Parkinson\u2019s disease - network meta-analysis. NPJ Parkinsons Dis. 9, 143. https:\/\/doi.org\/10.1038\/s41531-023-00589-8 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"94960_CR22","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","volume":"37","author":"T Martin","year":"2021","unstructured":"Martin, T. et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus Idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr. Med. Res. Opin. 37, 1779\u20131788. https:\/\/doi.org\/10.1080\/03007995.2021.1953456 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"94960_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/00004872-199609002-00004","volume":"14","author":"RH Fagard","year":"1996","unstructured":"Fagard, R. H., Staessen, J. A. & Thijs, L. Advantages and disadvantages of the meta-analysis approach. J. Hypertens. Suppl. 14, 9\u201312. https:\/\/doi.org\/10.1097\/00004872-199609002-00004 (1996). discussion S13.","journal-title":"J. Hypertens. Suppl."},{"key":"94960_CR24","doi-asserted-by":"publisher","first-page":"20632","DOI":"10.1038\/s41598-023-48067-8","volume":"13","author":"MT Pellecchia","year":"2023","unstructured":"Pellecchia, M. T. et al. The effects of Safinamide according to gender in Chinese parkinsonian patients. Sci. Rep. 13, 20632. https:\/\/doi.org\/10.1038\/s41598-023-48067-8 (2023).","journal-title":"Sci. Rep."},{"key":"94960_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost, W. H. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J. Neural Transm. (Vienna)  129, 723\u2013736. https:\/\/doi.org\/10.1007\/s00702-022-02465-w (2022).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"94960_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14802\/jmd.22196","volume":"16","author":"R Bhidayasiri","year":"2023","unstructured":"Bhidayasiri, R. et al. Safinamide as an adjunct to Levodopa in Asian and Caucasian patients with Parkinson\u2019s disease and motor fluctuations: A post hoc analysis of the SETTLE study. J. Mov. Disord. 16, 180\u2013190. https:\/\/doi.org\/10.14802\/jmd.22196 (2023).","journal-title":"J. Mov. Disord."},{"key":"94960_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox, S. H. et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov. Disord. 33, 1248\u20131266 (2018).","journal-title":"Mov. Disord."},{"key":"94960_CR28","doi-asserted-by":"publisher","first-page":"107103","DOI":"10.1016\/j.parkreldis.2024.107103","volume":"127","author":"R Bovenzi","year":"2024","unstructured":"Bovenzi, R. et al. Safinamide effect on sleep architecture of motor fluctuating Parkinson\u2019s disease patients: A polysomnographic rasagiline-controlled study. Parkinsonism Relat. Disord. 127, 107103 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"94960_CR29","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. Effects of MAO\u2013B inhibitors in life quality of Parkinson\u2019s disease patients: A systematic review and meta-analysis. Behav. Brain. Res.  115410 (2024).","DOI":"10.1016\/j.bbr.2024.115410"},{"key":"94960_CR30","doi-asserted-by":"crossref","unstructured":"Bette, S., Shpiner, D. S., Singer, C. & Moore, H. Safinamide in the management of patients with Parkinson\u2019s disease not stabilized on Levodopa: A review of the current clinical evidence. Ther. Clin. Risk Manag., 1737\u20131745 (2018).","DOI":"10.2147\/TCRM.S139545"},{"key":"94960_CR31","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","volume":"23","author":"FG Teixeira","year":"2018","unstructured":"Teixeira, F. G. et al. Safinamide: A new hope for Parkinson\u2019s disease? Drug Discov Today 23, 736\u2013744. https:\/\/doi.org\/10.1016\/j.drudis.2018.01.033 (2018).","journal-title":"Drug Discov Today"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94960-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94960-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94960-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T20:32:13Z","timestamp":1743021133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94960-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94960"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94960-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10502"}}